X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Insights

Innovest Global Inc. Signs Letter Of Intent to Acquire Commercial Energy Business

Yuvraj_pawp by Yuvraj_pawp
28th November 2017
in Insights
Innovest Global Inc. Signs Letter Of Intent to Acquire Commercial Energy Business

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Innovest Global Inc. announced that it has signed a Letter of Intent to acquire a Commercial Energy business, which will launch a Commercial Energy Division for the diversified holding company, and add a 7-figure revenue stream to Innovest’s top-line.

“We’re focusing on a few key industries that we believe have significant growth potential,” said Innovest CEO, Dan Martin, “Certainly, new trends and technologies make Commercial Energy an attractive opportunity, and considering our existing business to business sales division, it’s also a great strategic fit.”

The Letter of Intent is subject to a confidentiality agreement. However, Innovest is fully equipped to execute the transaction, and does not need any financial or other arrangements to close. Preliminary due diligence has been completed, and once Innovest completes final due diligence, the Parties expect the transaction to close by January, 2018.

The target company features executives, each having more than 15 years experience at the highest level in their field, and excited to join the Innovest team. After a very successful history, they expanded the business to reflect the current needs of commercial and industrial clients. They now provide an all-in-one offering: procurement, management, and efficiency solutions for commercial and industrial clients. In seven months since the expansion, the new offerings added annual run rate revenue of $1 million, which is growing rapidly. It is a scalable model, expandable geographically.

According to the 2017 Power and Utilities Trends report by PwC, current trends in the industry are a “Blueprint for a Service Based Model”, such as the model Innovest has found in this company. Energy management, emerging technologies, equipment use monitoring, are all part of a revolutionary new way of managing cost and efficiency in a technologically driven economy, with increasing energy demands. “We want to be on the front end of these trends, with an amazing team and sales momentum, and we get all three with this transaction,” said Martin.

Innovest’s diversified holding company model, and their focus on efficient customer acquisition and reduced risk, are the core tenets of what the company hopes will create significant value for their shareholders.

For more information contact
info@innovestglobal.com
Innovest, Investor Relations Matt Rego
216.815.1122
http://www.innovestglobal.com

Previous Post

Stealth BioTherapeutics Granted Fast Track Designation For The Treatment Of Barth Syndrome

Next Post

Synpromics announces collaboration with UCL to develop revolutionary gene therapy for Parkinson’s Disease

Related Posts

wearable drug delivery devices
Insights

Wearable Drug Delivery Devices for On-Demand Care

27th September 2025
high volume injectable formulations
Insights

Overcoming Challenges in High-Volume Injectable Formulations

27th September 2025
Insights

Smart Drug Delivery Systems for Patient Care

27th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
active pharmaceutical ingredients supply chain
Drug Development

Future of Active Pharmaceutical Ingredients Supply

26th September 2025
pharmaceutical excipients for new therapies
Drug Development

Advances in Pharmaceutical Excipients for New Therapies

26th September 2025
Next Post

Synpromics announces collaboration with UCL to develop revolutionary gene therapy for Parkinson’s Disease

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In